Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 8/20 | 0.86 |
| ▸ | KDR | P35968 | 6/20 | 0.86 |
| ▸ | ABL1 | P00519 | 6/20 | 0.86 |
| ▸ | FLT3 | P36888 | 4/20 | 0.86 |
| ▸ | KIT | P10721 | 3/20 | 0.86 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.86 |
| ▸ | TEK | Q02763 | 3/20 | 0.86 |
| ▸ | STK10 | O94804 | 2/20 | 0.86 |
| ▸ | BRAF | P15056 | 2/20 | 0.86 |
| ▸ | FLT1 | P17948 | 2/20 | 0.86 |
| ▸ | CDK11B | P21127 | 2/20 | 0.86 |
| ▸ | CDK2 | P24941 | 2/20 | 0.86 |
| ▸ | FLT4 | P35916 | 2/20 | 0.86 |
| ▸ | CDK7 | P50613 | 2/20 | 0.86 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.86 |
| ▸ | CDK3 | Q00526 | 2/20 | 0.86 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.86 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.86 |
| ▸ | HIPK1 | Q86Z02 | 2/20 | 0.86 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060759 | 0.92 | KIT (1.00) | RETKDRABL1FLT3KIT | |
| SCHEMBL29381604 | 0.92 | KIT (1.00) | RETKDRABL1FLT3KIT | |
| SCHEMBL1696179 | 0.92 | KIT (1.00) | RETKDRABL1FLT3KIT | |
| SCHEMBL1705135 | 0.92 | KIT (0.91) | RETKDRABL1FLT3KIT | |
| SCHEMBL1704344 | 0.88 | ABL1 (0.87) | RETKDRABL1FLT3KIT | |
| SCHEMBL1705307 | 0.84 | KIT (0.79) | RETKDRABL1FLT3KIT | |
| SCHEMBL1696182 | 0.84 | KIT (0.85) | RETKDRABL1FLT3KIT | |
| SCHEMBL1696293 | 0.84 | KIT (0.85) | RETKDRABL1FLT3KIT | |
| SCHEMBL25639500 | 0.83 | KIT (0.84) | RETKDRABL1FLT3KIT | |
| SCHEMBL25639509 | 0.83 | KIT (0.83) | RETKDRABL1FLT3KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148448-A9 | BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20220127284-A1 | BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | GRAY NATHANAEL S (US) | 2022-04-28 | — | — | US | disclosed |
| US-9505784-B2 | Fused 2-aminothiazole compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505784-B2 | Fused 2-aminothiazole compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150094315-A1 | FUSED 2-AMINOTHIAZOLE COMPOUNDS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150094315-A1 | FUSED 2-AMINOTHIAZOLE COMPOUNDS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8765747-B2 | Fused 2-aminothiazole compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765747-B2 | Fused 2-aminothiazole compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120088766-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088766-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2010144909-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088766-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | OAT, OTC, DLD | RET 2038/4885KDR 1877/4885ABL1 1023/4885 |
| US-20230148448-A9 | BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK2, JAK1, JAK3 | RET 111/4885KDR 477/4885ABL1 15/4885 |
| US-20220127284-A1 | BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK2, JAK1, JAK3 | RET 111/4885KDR 477/4885ABL1 15/4885 |
| US-20150094315-A1 | FUSED 2-AMINOTHIAZOLE COMPOUNDS | GOT2, OAT, ABAT | RET 1896/4885KDR 2363/4885ABL1 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.